What is Ophthalmic Viscosurgical Devices Market?
Ophthalmic viscosurgical devices are essential apparatus for the anterior segment surgeon, are Ophthalmic viscosurgical devices transparent, gel-like substances that have viscous and elastic properties. Composed of sodium hyaluronate, chondroitin sulfate, and methylcellulose, they vary in molecular weights and viscosities, and can be classified into two general categories: cohesive and dispersive. Ophthalmic viscosurgical devices are used during surgery in order to maintain and preserve space, displace and stabilize tissue, and coat and protect tissue. Examples of these functions during cataract surgery include: maintaining the anterior chamber during the capsulorhexis and IOL insertion, preventing iris prolapse and trapping nuclear fragments, and protecting the corneal endothelium from turbulence, lens material, and ultrasound energy, respectively. Since their introduction in the early 1970s, ophthalmic viscosurgical devices (OVD) have revolutionized cataract surgery as well as IOL implantation. According to the research done by World Health Organization, cataract is responsible for half of the reversible blindness on the planet. The Interregional Association of Ophthalmologists reports that about half a million cataract operations are performed in the Russian Federation annually.
The market study is being classified by Type (Dispersive, Cohesive and Combined ), by Application (Cataract surgery, Corneal surgery and penetrating keratoplasty, Glaucoma surgery, Ocular trauma and Posterior segment surgery) and major geographies with country level break-up.
Abbott Medical Optics (United States), Carl-Zeiss (Australia), Novartis (Switzerland), Johnson & Johnson (United States), Roche(Switzerland), Pfizer(United States), Allergan(United States), Hyaltech (United Kingdom), Valeant Pharma(United States), CIMA Technology(United States) and Rayner(United Kingdom) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Ophthalmic Viscosurgical Devices market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Ophthalmic Viscosurgical Devices market by Type, Application and Region.
On the basis of geography, the market of Ophthalmic Viscosurgical Devices has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Improving access to ophthalmic care facilities
- Rising awareness about ocular disorders
- R&D department and laboratories support for Ophthalmic Viscosurgical Devices and implement production control at all stages
- High Cost associated with the Ophthalmic Viscosurgical Devices
- A prominent surge in the aging population prone to cataract problems is likely to embellish the expansion of the Ophthalmic Viscosurgical Devices (OVD) Market over the forecast timespan
- Lack of skilled professional
In Jul 2020 Solopharm has become the main drug organization in Russia that has built up innovation for the creation of consolidated ophthalmic viscosurgical gadgets (OVDs) in light of hyaluronic corrosive and chondroitin. The innovation is remarkable for the Russian drug industry and makes it conceivable to actualize quality control at all phases of creation. At present Solopharm keeps on building new creation lines while expanding its yield and extending its geographic presence. As of June 1, 2020, the plant had 27 computerized lines working every minute of every day. The organization's own R&D division and research facilities uphold full-cycle advancement of OVDs and execute creation control at all stages.
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Ophthalmic Viscosurgical Devices Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase